215 related articles for article (PubMed ID: 22180803)
1. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine.
Dorlo TP; van Thiel PP; Schoone GJ; Stienstra Y; van Vugt M; Beijnen JH; de Vries PJ
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1436. PubMed ID: 22180803
[TBL] [Abstract][Full Text] [Related]
2. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Apigenin and Miltefosine Combination Therapy against Experimental Cutaneous Leishmaniasis.
Emiliano YSS; Almeida-Amaral EE
J Nat Prod; 2018 Aug; 81(8):1910-1913. PubMed ID: 30095915
[TBL] [Abstract][Full Text] [Related]
4. In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up.
Coelho AC; Trinconi CT; Costa CH; Uliana SR
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004720. PubMed ID: 27416021
[No Abstract] [Full Text] [Related]
5. Investigation of anti-leishmanial efficacy of miltefosine and ketoconazole loaded on nanoniosomes.
Nazari-Vanani R; Vais RD; Sharifi F; Sattarahmady N; Karimian K; Motazedian MH; Heli H
Acta Trop; 2018 Sep; 185():69-76. PubMed ID: 29733808
[TBL] [Abstract][Full Text] [Related]
6. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
Calvopina M; Gomez EA; Sindermann H; Cooper PJ; Hashiguchi Y
Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC
Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653
[TBL] [Abstract][Full Text] [Related]
8. Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions.
Griewank K; Gazeau C; Eichhorn A; von Stebut E
Antimicrob Agents Chemother; 2010 Feb; 54(2):652-9. PubMed ID: 19995922
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
[TBL] [Abstract][Full Text] [Related]
10. New insights with miltefosine unresponsiveness in Brazilian Leishmania infantum isolates.
Bhattacharya A; Ouellette M
EBioMedicine; 2018 Nov; 37():13-14. PubMed ID: 30314891
[No Abstract] [Full Text] [Related]
11. Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.
Fortin A; Caridha DP; Leed S; Ngundam F; Sena J; Bosschaerts T; Parriott S; Hickman MR; Hudson TH; Grogl M
PLoS Negl Trop Dis; 2014 Sep; 8(9):e3144. PubMed ID: 25210745
[TBL] [Abstract][Full Text] [Related]
12. Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers.
Eichner S; Thoma-Uszynski S; Herrgott I; Sebald H; Debus A; Tsianakas A; Ehrchen J; Harms G; Simon M; Sunderkötter C; Bogdan C
Eur J Dermatol; 2013 Apr; 23(2):218-23. PubMed ID: 23557633
[TBL] [Abstract][Full Text] [Related]
13. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
14. Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome.
Stoeckle M; Holbro A; Arnold A; Neumayr A; Weisser M; Blum J
Acta Trop; 2013 Oct; 128(1):168-70. PubMed ID: 23871798
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of a married couple for American leishmaniasis with miltefosine.
Wöhrl S; Schnedl J; Auer H; Walochnik J; Stingl G; Geusau A
J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):258-9. PubMed ID: 18211436
[No Abstract] [Full Text] [Related]
16. Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
Castro MDM; Cossio A; Velasco C; Osorio L
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005515. PubMed ID: 28379954
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Wijnant GJ; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607026
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous leishmaniasis after travel to Cyprus and successful treatment with miltefosine.
Poeppl W; Walochnik J; Pustelnik T; Auer H; Mooseder G
Am J Trop Med Hyg; 2011 Apr; 84(4):562-5. PubMed ID: 21460010
[TBL] [Abstract][Full Text] [Related]
19. Successful Treatment of Disseminated Cutaneous Leishmaniasis With Liposomal Amphotericin B and Miltefosine in an Eight-year-old Girl.
Hamzavi SS; Sanaei Dashti A; Kadivar MR; Pouladfar G; Pourabbas B
Pediatr Infect Dis J; 2018 Mar; 37(3):275-277. PubMed ID: 29424815
[TBL] [Abstract][Full Text] [Related]
20. Post-kala-azar dermal leishmaniasis due to Leishmania infantum in an HIV-negative patient treated with miltefosine.
Monge-Maillo B; Norman FF; Chamorro-Tojeiro S; Gioia F; Pérez-Molina JA; Chicharro C; Moreno J; López-Vélez R
J Travel Med; 2022 Nov; 29(7):. PubMed ID: 34668558
[No Abstract] [Full Text] [Related]
[Next] [New Search]
